Monte Rosa Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Monte Rosa Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-0.9×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Higher than 62% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-5.2×Operating cash was negative last year, while some debt falls due within a year.
Higher than 59% of Healthcare companies in United States.
Cash Cushion Ratio
+36%Cash, after subtracting all debt, equals 36% of its market value (net cash).
Higher than 72% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Monte Rosa Therapeutics, Inc. made a loss over the last year. Monte Rosa Therapeutics, Inc. owes $0.29 for every $1 it owns. Monte Rosa Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossMonte Rosa Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.95The share price is 1.95 times Monte Rosa Therapeutics, Inc.'s book value per share, lower than 60% of Healthcare companies in United States.
Market cap
$948 MThe total market value of all of Monte Rosa Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 63% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$487 MWhat Monte Rosa Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$5.71Net worth divided by the number of shares. The share price of $11.11 is 1.9 times this, which is the P/B above.
Return on equity (ROE)
-42.7%Monte Rosa Therapeutics, Inc. lost 42.7% of its shareholders' money over the last year, higher than 53% of Healthcare companies in United States.
Owes vs Owns
0.29×Monte Rosa Therapeutics, Inc. owes $0.29 for every $1 it owns (low), lower than 60% of Healthcare companies in United States.
Dividend yield
NoneMonte Rosa Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+64%Revenue rose 64% in the year to Dec 2025.
Profit growth
LossMonte Rosa Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-31.2%Monte Rosa Therapeutics, Inc. lost $31 for every $100 of revenue.
Cash vs debt
Net cashMonte Rosa Therapeutics, Inc. held $338 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Monte Rosa Therapeutics, Inc.: $948 M ÷ $487 M (30 Jun 2026) = 1.9.
What is Monte Rosa Therapeutics, Inc.'s return on equity?
Monte Rosa Therapeutics, Inc. lost 42.7% of its shareholders' money over the last year, higher than 53% of Healthcare companies in United States.
How much does Monte Rosa Therapeutics, Inc. owe compared with what it owns?
Monte Rosa Therapeutics, Inc. owes $0.29 for every $1 it owns (low), lower than 60% of Healthcare companies in United States.
Does Monte Rosa Therapeutics, Inc. pay a dividend?
No. Monte Rosa Therapeutics, Inc. does not currently pay a dividend.
Is Monte Rosa Therapeutics, Inc.'s revenue growing?
Revenue rose 64% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.